



**International Conference on Innovations in Pharmacy and
Biotechnology (ICIPB – 2022)
27th March, 2022, Vijayawada, Andhra Pradesh, India**

CERTIFICATE NO : ICIPB /2022/ C0322307

**AN INSILCO DRUG DESIGNING FOR BREAST CANCER IN
HOMOSAPIENS**

SHUBHI SINHA, ARVIND KUMAR ARYA

**M. Tech, Department of Biotechnology,
Noida Institute of Engineering and Technology, Gr. Noida, (U.P)**

ABSTRACT

The breast cancer susceptibility gene BRCA1 is a nuclear phosphoprotein which functions as a tumour suppressor. The protein BRCA1 is responsible for breast cancer. Breast Cancer is one of the most common cancers in woman other than skin cancer. To treat the breast cancer, we have used Insilco methods for drug discovery. We have developed a new ligand which can act as drug. I identified and analysed active sites and suggested potential drug molecules that can bind to these sites specifically. I analysed the target proteins for possible binding sites, generate molecules(ligands) for further procedure of docking and interactions.